↓ Skip to main content

Targeting energy metabolism via the mitochondrial pyruvate carrier as a novel approach to attenuate neurodegeneration

Overview of attention for article published in Molecular Neurodegeneration, May 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (86th percentile)
  • Good Attention Score compared to outputs of the same age and source (72nd percentile)

Mentioned by

news
1 news outlet
twitter
13 X users
facebook
2 Facebook pages

Citations

dimensions_citation
59 Dimensions

Readers on

mendeley
105 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Targeting energy metabolism via the mitochondrial pyruvate carrier as a novel approach to attenuate neurodegeneration
Published in
Molecular Neurodegeneration, May 2018
DOI 10.1186/s13024-018-0260-x
Pubmed ID
Authors

Emmanuel Quansah, Wouter Peelaerts, J. William Langston, David K. Simon, Jerry Colca, Patrik Brundin

Abstract

Several molecular pathways are currently being targeted in attempts to develop disease-modifying therapies to slow down neurodegeneration in Parkinson's disease. Failure of cellular energy metabolism has long been implicated in sporadic Parkinson's disease and recent research on rare inherited forms of Parkinson's disease have added further weight to the importance of energy metabolism in the disease pathogenesis. There exists a new class of anti-diabetic insulin sensitizers in development that inhibit the mitochondrial pyruvate carrier (MPC), a protein which mediates the import of pyruvate across the inner membrane of mitochondria. Pharmacological inhibition of the MPC was recently found to be strongly neuroprotective in multiple neurotoxin-based and genetic models of neurodegeneration which are relevant to Parkinson's disease. In this review, we summarize the neuroprotective effects of MPC inhibition and discuss the potential putative underlying mechanisms. These mechanisms involve augmentation of autophagy via attenuation of the activity of the mammalian target of rapamycin (mTOR) in neurons, as well as the inhibition of neuroinflammation, which is at least partly mediated by direct inhibition of MPC in glia cells. We conclude that MPC is a novel and potentially powerful therapeutic target that warrants further study in attempts to slow Parkinson's disease progression.

X Demographics

X Demographics

The data shown below were collected from the profiles of 13 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 105 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 105 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 21 20%
Researcher 18 17%
Student > Master 15 14%
Student > Bachelor 11 10%
Other 6 6%
Other 12 11%
Unknown 22 21%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 22 21%
Neuroscience 16 15%
Agricultural and Biological Sciences 14 13%
Medicine and Dentistry 13 12%
Pharmacology, Toxicology and Pharmaceutical Science 10 10%
Other 6 6%
Unknown 24 23%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 December 2021.
All research outputs
#2,038,880
of 22,711,242 outputs
Outputs from Molecular Neurodegeneration
#205
of 844 outputs
Outputs of similar age
#45,972
of 329,336 outputs
Outputs of similar age from Molecular Neurodegeneration
#6
of 18 outputs
Altmetric has tracked 22,711,242 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 844 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.1. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 329,336 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.